AlzChem nine-month EBITDA rises 8% to EUR 93.2 million
Bitget2026/10/29 05:56- Alzchem's nine-month 2026 EBITDA rose 8% to EUR 93.2 million; sales increased to EUR 443.8 million.
- Specialty Chemicals EBITDA climbed 17% to EUR 91.5 million, while segment sales grew 11% to EUR 312.7 million.
- Technical commissioning of additional German guanidine nitrate and nitroguanidine capacity began in the third quarter; first sales are expected in fourth-quarter 2026.
- Management confirmed its 2026 outlook for sales of approximately EUR 600 million and EBITDA of around EUR 126 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
